Get the Stockscreener App
8.20
1.09%
-0.09
After Hours:
8.20
Wave Life Sciences Ltd stock is traded at $8.20, with a volume of 1.22M.
It is down -1.09% in the last 24 hours and up +42.86% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$8.29
Open:
$8.33
24h Volume:
1.22M
Relative Volume:
1.00
Market Cap:
$1.02B
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-6.0294
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
+53.56%
1M Performance:
+42.86%
6M Performance:
+32.90%
1Y Performance:
+42.61%
1-Day Range:
$8.07
$8.49
1-Week Range:
$6.37
$9.92
52-Week Range:
$3.50
$9.92
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference - The Manila Times
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference - GlobeNewswire
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference - StockTitan
WaVe Life Sciences' SWOT analysis: biotech stock's pipeline progress faces hurdles - Investing.com UK
Driehaus Capital Management LLC Purchases 348,300 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Sells $154,314.00 in Stock - MarketBeat
Wave Life Sciences gains on data for Duchenne therapy - MSN
Wave Life Sciences stock boosted by pipeline advancements and fundingJPMorgan - Investing.com South Africa
Insider Sale: CFO Kyle Moran Sells 17,146 Shares of WAVE Life Sc - GuruFocus.com
Wave Life Sciences CFO sells shares worth over $150k - Investing.com India
Wave Life Sciences CFO sells shares worth over $150k By Investing.com - Investing.com Australia
Wave Life Sciences CFO sells shares worth over $150k By Investing.com - Investing.com South Africa
Wave Life Sciences CFO sells shares worth over $150k - Investing.com
Wave Life Sciences CFO sells shares worth over $150k By Investing.com - Investing.com UK
JPMorgan Chase & Co. Initiates Coverage on Wave Life Sciences (NASDAQ:WVE) - MarketBeat
HC Wainwright Weighs in on Wave Life Sciences Ltd.'s FY2025 Earnings (NASDAQ:WVE) - MarketBeat
Wave Life Sciences rises; JP Morgan resumes coverage with 'overweight' - XM
Wave Life Sciences stock boosted by pipeline advancements and fundingJPMorgan - Investing.com India
Wave Life Sciences’ $200M Public Offering and Operational Extension - TipRanks
Wave Life Sciences shares drop after larger-than-targeted equity raise - XM
Wave Life Sciences (NASDAQ:WVE) Shares Gap Down to $9.01 - MarketBeat
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut - Benzinga
WAVE Life Sciences shares hold buy rating on recent performance By Investing.com - Investing.com Australia
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - StockTitan
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
Mizuho maintains Outperform rating on WAVE Life Sciences shares - Investing.com India
WAVE Life Sciences shares hold buy rating on recent performance - Investing.com India
WAVE Life Sciences shares hold buy rating on recent performance - Investing.com
Mizuho maintains Outperform rating on WAVE Life Sciences shares - Investing.com
Wave Life Sciences (NASDAQ:WVE) Reaches New 52-Week High Following Analyst Upgrade - MarketBeat
WVE Stock Soars On Upbeat Efficacy Data From Muscle Disease Study - Barchart
Wave Life Sciences (NASDAQ:WVE) Given New $22.00 Price Target at HC Wainwright - MarketBeat
Affinity Asset Advisors LLC Boosts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Affinity Asset Advisors LLC Has $1.87 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study - Zacks Investment Research
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study - Yahoo Finance
Wave’s stock swells as it eyes approval following Phase II DMD victory - Clinical Trials Arena
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump - Simply Wall St
Items Tagged with 'WVE-N531' - BioWorld Online
Wave Life Sciences soars on positive DMD trial results - The Pharma Letter
Riding high on new Duchenne data, Wave files $175m offering - pharmaphorum
WAVE Life Sciences (NASDAQ:WVE) Stock Quotes, Forecast and News Summary - Benzinga
Wave Life And Capricor Surge Forward With HopeAre These Stocks In Your Portfolio? - RTTNews
Wave claims early lead in second-generation exon 53 skipping - BioCentury
Wave Life Sciences shares pop 50% on positive clinical data for common type of muscular dystrophy - Mugglehead
WAVE Life Sciences stock target lifted, holds buy on positive study data - Investing.com Australia
Wave Life Sciences reports promising DMD trial results By Investing.com - Investing.com Canada
Wave Life Sciences announces $175 million share offering By Investing.com - Investing.com Canada
Wave Life Sciences stock hits 52-week high at $7.67 By Investing.com - Investing.com Canada
Form 424B3 Wave Life Sciences Ltd. - StreetInsider.com
Wave Life Sciences stock hits 52-week high at $7.67 By Investing.com - Investing.com Australia
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):